LIGAND PHARMACEUTICALS (LGND) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$301.81
+2.3% on the day
+65.5% over 12 months
52-week range $177.73 – $322.61
Share price and insider trades
LGND closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$34.7M
Insiders buying0
Insiders selling9
LIGAND PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $34.7M of LGND stock on the open market.
Get emailed when insiders cluster-buy stocks like LGND
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
LGND insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $1.5M | 6 |
| Q3 2026 | — | 0 | $16.1M | 26 |
| Q2 2026 | — | 0 | $8.6M | 41 |
| Q1 2026 | — | 0 | $5.8M | 42 |
| Q4 2025 | — | 0 | $2.8M | 20 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.9×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 LIGAND PHARMACEUTICALS INC insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $34.7M. 116 of 135 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,97634,045 held (−5%) | $303.54 | $600K | -0.6% | — |
| Oct 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,53532,510 held (−5%) | $304.52 | $467K | -0.9% | — |
| Oct 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 83336,021 held (−2%) | $302.51 | $252K | -0.2% | — |
| Oct 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 40432,106 held (−1%) | $306.18 | $124K | -1.4% | — |
| Oct 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 23531,871 held (−1%) | $307.19 | $72K | -1.8% | — |
| Oct 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1731,854 held (−0%) | $307.74 | $5K | -1.9% | — |
| Sep 14SEC | Martine ZimmermannDirector | Sell | 1,2003,897 held (−24%) | $285.00 | $342K | +5.9% | — |
| Sep 8SEC | Andrew ReardonGeneral Counsel | Sell Plan | 2,11537,299 held (−5%) | $286.36 | $606K | +5.4% | — |
| Sep 8SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,80039,414 held (−4%) | $285.17 | $513K | +5.8% | — |
| Sep 8SEC | Andrew ReardonGeneral Counsel | Sell Plan | 40036,514 held (−1%) | $288.98 | $116K | +4.4% | — |
| Sep 8SEC | Andrew ReardonGeneral Counsel | Sell Plan | 38536,914 held (−1%) | $287.53 | $111K | +5.0% | — |
| Sep 8SEC | Andrew ReardonGeneral Counsel | Sell Plan | 30041,214 held (−1%) | $283.99 | $85K | +6.3% | — |
| Aug 14SEC | Octavio EspinozaCFO | Sell Plan | 31,64127,696 held (−53%) | $292.07 | $9.2M | +3.3% | — |
| Aug 14SEC | Jason HaasDirector | Sell | 7,1383,981 held (−64%) | $292.81 | $2.1M | +3.1% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,21443,973 held (−3%) | $287.77 | $349K | +4.9% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,03245,187 held (−2%) | $286.80 | $296K | +5.2% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 99141,923 held (−2%) | $291.71 | $289K | +3.5% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 50343,114 held (−1%) | $289.80 | $146K | +4.1% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 40941,514 held (−1%) | $292.82 | $120K | +3.1% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 35643,617 held (−1%) | $288.75 | $103K | +4.5% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 20042,914 held (−0%) | $290.60 | $58K | +3.9% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 15746,219 held (−0%) | $285.74 | $45K | +5.6% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 10546,409 held (−0%) | $284.14 | $30K | +6.2% | — |
| Aug 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 3346,376 held (−0%) | $284.55 | $9K | +6.1% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,11944,895 held (−2%) | $311.72 | $349K | -3.2% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,08143,814 held (−2%) | $312.28 | $338K | -3.4% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 90042,114 held (−2%) | $315.78 | $284K | -4.4% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 70043,114 held (−2%) | $313.46 | $219K | -3.7% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 60041,514 held (−1%) | $317.15 | $190K | -4.8% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 39646,118 held (−1%) | $308.99 | $122K | -2.3% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 10446,014 held (−0%) | $310.20 | $32K | -2.7% | — |
| Jul 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 10043,014 held (−0%) | $314.58 | $31K | -4.1% | — |
| Jun 18SEC | Stephen L SabbaDirector | Sell | 2,14533,629 held (−6%) | $254.00 | $545K | +18.8% | — |
| Jun 15SEC | Jason HaasDirector | Sell | 3,4614,981 held (−41%) | $256.08 | $886K | +17.9% | — |
| Jun 15SEC | Jason HaasDirector | Sell | 3,0008,442 held (−26%) | $255.01 | $765K | +18.4% | — |
| Jun 12SEC | Jason AryehDirector | Sell | 4,500102,580 held (−4%) | $250.00 | $1.1M | +20.7% | — |
| Jun 12SEC | John L LamattinaDirector | Sell | 3,40526,969 held (−11%) | $251.62 | $857K | +19.9% | — |
| Jun 12SEC | John L LamattinaDirector | Sell | 69730,374 held (−2%) | $249.53 | $174K | +21.0% | — |
| Jun 12SEC | Jason AryehDirector | Sell | 500107,080 held (−0%) | $250.00 | $125K | +20.7% | — |
| Jun 12SEC | John L LamattinaDirector | Sell | 25731,303 held (−1%) | $247.22 | $64K | +22.1% | — |
| Jun 12SEC | John L LamattinaDirector | Sell | 23231,071 held (−1%) | $248.11 | $58K | +21.6% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,43243,782 held (−3%) | $225.97 | $324K | +33.6% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,21641,582 held (−3%) | $229.47 | $279K | +31.5% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 67745,214 held (−1%) | $225.20 | $152K | +34.0% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 58442,798 held (−1%) | $228.57 | $133K | +32.0% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 49145,891 held (−1%) | $223.95 | $110K | +34.8% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 40043,382 held (−1%) | $226.78 | $91K | +33.1% | — |
| Jun 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 20041,382 held (−0%) | $230.41 | $46K | +31.0% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 1,57541,786 held (−4%) | $223.50 | $352K | +35.0% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 45941,786 held (−1%) | $224.00 | $103K | +34.7% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 16542,007 held (−0%) | $231.87 | $38K | +30.2% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 11641,786 held (−0%) | $234.09 | $27K | +28.9% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 10541,902 held (−0%) | $232.57 | $24K | +29.8% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 8042,173 held (−0%) | $227.37 | $18K | +32.7% | — |
| May 14SEC | John W KozarichDirector | Sell Plan | 142,172 held (−0%) | $229.87 | $230 | +31.3% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,42042,182 held (−3%) | $232.92 | $331K | +29.6% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 93244,850 held (−2%) | $228.75 | $213K | +31.9% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 80041,382 held (−2%) | $234.02 | $187K | +29.0% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 78043,602 held (−2%) | $232.04 | $181K | +30.1% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 60045,782 held (−1%) | $227.45 | $136K | +32.7% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 37044,382 held (−1%) | $230.87 | $85K | +30.7% | — |
| May 4SEC | Andrew ReardonGeneral Counsel | Sell Plan | 9844,752 held (−0%) | $229.71 | $23K | +31.4% | — |
| Apr 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,30244,620 held (−3%) | $199.72 | $260K | +51.1% | — |
| Apr 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,23843,382 held (−3%) | $200.94 | $249K | +50.2% | — |
| Apr 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 96341,719 held (−2%) | $203.22 | $196K | +48.5% | — |
| Apr 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 70042,682 held (−2%) | $201.90 | $141K | +49.5% | — |
| Apr 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 46045,922 held (−1%) | $198.85 | $91K | +51.8% | — |
| Apr 2SEC | Andrew ReardonGeneral Counsel | Sell Plan | 33741,382 held (−1%) | $204.50 | $69K | +47.6% | — |
| Apr 2SEC | John W KozarichDirector | Sell Plan | 15942,253 held (−0%) | $204.26 | $32K | +47.8% | — |
| Apr 2SEC | John W KozarichDirector | Sell Plan | 14642,574 held (−0%) | $199.97 | $29K | +50.9% | — |
| Apr 2SEC | John W KozarichDirector | Sell Plan | 7942,455 held (−0%) | $202.42 | $16K | +49.1% | — |
| Apr 2SEC | John W KozarichDirector | Sell Plan | 4342,412 held (−0%) | $202.91 | $9K | +48.7% | — |
| Apr 2SEC | John W KozarichDirector | Sell Plan | 4042,534 held (−0%) | $201.24 | $8K | +50.0% | — |
| Mar 31SEC | John L LamattinaDirector | Sell | 2,16130,724 held (−7%) | $200.76 | $434K | +50.3% | — |
| Mar 25SEC | Stephen L SabbaDirector | Sell | 1,00032,793 held (−3%) | $207.87 | $208K | +45.2% | — |
| Mar 13SEC | Octavio EspinozaCFO | Sell Plan | 3,05721,010 held (−13%) | $225.00 | $688K | +34.1% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 3,41321,662 held (−14%) | $208.80 | $713K | +44.5% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 2,45725,075 held (−9%) | $207.91 | $511K | +45.2% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 1,58827,532 held (−5%) | $206.89 | $329K | +45.9% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,44638,011 held (−4%) | $208.12 | $301K | +45.0% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 1,45729,120 held (−5%) | $205.79 | $300K | +46.7% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 1,14236,869 held (−3%) | $208.87 | $239K | +44.5% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 95032,685 held (−3%) | $201.73 | $192K | +49.6% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 74330,577 held (−2%) | $204.74 | $152K | +47.4% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 69731,988 held (−2%) | $202.79 | $141K | +48.8% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 69833,635 held (−2%) | $201.09 | $140K | +50.1% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 69934,386 held (−2%) | $198.71 | $139K | +51.9% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 66831,320 held (−2%) | $203.63 | $136K | +48.2% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 61239,457 held (−2%) | $207.01 | $127K | +45.8% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 46040,409 held (−1%) | $205.18 | $94K | +47.1% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 34040,069 held (−1%) | $206.37 | $70K | +46.2% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 30041,069 held (−1%) | $201.70 | $61K | +49.6% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 20741,462 held (−0%) | $199.96 | $41K | +50.9% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 20040,869 held (−0%) | $204.17 | $41K | +47.8% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 10041,669 held (−0%) | $199.01 | $20K | +51.7% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 10041,769 held (−0%) | $197.70 | $20K | +52.7% | — |
| Mar 6SEC | Andrew ReardonGeneral Counsel | Sell Plan | 9341,369 held (−0%) | $200.62 | $19K | +50.4% | — |
| Mar 6SEC | Octavio EspinozaCFO | Sell Plan | 5334,333 held (−0%) | $200.08 | $11K | +50.8% | — |
| Mar 5SEC | Stephen L SabbaDirector | Sell | 2,03433,793 held (−6%) | $201.50 | $410K | +49.8% | — |
| Mar 4SEC | John W KozarichDirector | Sell Plan | 20442,936 held (−0%) | $199.69 | $41K | +51.1% | — |
| Mar 4SEC | John W KozarichDirector | Sell Plan | 8342,812 held (−0%) | $201.65 | $17K | +49.7% | — |
| Mar 4SEC | John W KozarichDirector | Sell Plan | 5042,762 held (−0%) | $202.54 | $10K | +49.0% | — |
| Mar 4SEC | John W KozarichDirector | Sell Plan | 4743,140 held (−0%) | $197.14 | $9K | +53.1% | — |
| Mar 4SEC | John W KozarichDirector | Sell Plan | 4242,720 held (−0%) | $203.57 | $9K | +48.3% | — |
| Mar 4SEC | John W KozarichDirector | Sell Plan | 4142,895 held (−0%) | $200.40 | $8K | +50.6% | — |
| Feb 4SEC | John W KozarichDirector | Sell Plan | 38143,210 held (−1%) | $196.36 | $75K | +53.7% | — |
| Feb 4SEC | John W KozarichDirector | Sell Plan | 3943,615 held (−0%) | $191.00 | $7K | +58.0% | — |
| Feb 4SEC | John W KozarichDirector | Sell Plan | 2343,187 held (−0%) | $197.20 | $5K | +53.0% | — |
| Feb 4SEC | John W KozarichDirector | Sell Plan | 2343,591 held (−0%) | $195.61 | $4K | +54.3% | — |
| Feb 4SEC | John W KozarichDirector | Sell Plan | 143,614 held (−0%) | $192.18 | $192 | +57.0% | — |
| Jan 6SEC | John W KozarichDirector | Sell Plan | 20743,700 held (−0%) | $190.27 | $39K | +58.6% | — |
| Jan 6SEC | John W KozarichDirector | Sell Plan | 10243,907 held (−0%) | $188.96 | $19K | +59.7% | — |
| Jan 6SEC | John W KozarichDirector | Sell Plan | 9144,009 held (−0%) | $187.95 | $17K | +60.6% | — |
| Jan 6SEC | John W KozarichDirector | Sell Plan | 4643,654 held (−0%) | $192.40 | $9K | +56.9% | — |
| Jan 6SEC | John W KozarichDirector | Sell Plan | 2144,100 held (−0%) | $186.59 | $4K | +61.8% | — |
| Dec 16SEC | Octavio EspinozaCFO | Sell | 1,80426,186 held (−6%) | $188.31 | $340K | +60.3% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 17944,317 held (−0%) | $194.76 | $35K | +55.0% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 9244,174 held (−0%) | $197.72 | $18K | +52.6% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 9244,496 held (−0%) | $193.86 | $18K | +55.7% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 4744,270 held (−0%) | $195.80 | $9K | +54.1% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 3044,121 held (−0%) | $200.02 | $6K | +50.9% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 2344,151 held (−0%) | $199.22 | $5K | +51.5% | — |
| Dec 3SEC | John W KozarichDirector | Sell Plan | 444,266 held (−0%) | $196.35 | $785 | +53.7% | — |
| Nov 12SEC | Nancy Ryan GrayDirector | Sell | 3,5568,094 held (−31%) | $205.45 | $731K | +46.9% | — |
| Nov 12SEC | Nancy Ryan GrayDirector | Sell | 3,0158,094 held (−27%) | $205.45 | $619K | +46.9% | — |
| Nov 12SEC | John L LamattinaDirector | Sell | 2,14530,724 held (−7%) | $205.45 | $441K | +46.9% | — |
| Nov 12SEC | John L LamattinaDirector | Sell | 2,03430,724 held (−6%) | $205.45 | $418K | +46.9% | — |
| Nov 5SEC | John W KozarichDirector | Sell Plan | 20744,715 held (−0%) | $191.25 | $40K | +57.8% | — |
| Nov 5SEC | John W KozarichDirector | Sell Plan | 12744,588 held (−0%) | $192.38 | $24K | +56.9% | — |
| Nov 5SEC | John W KozarichDirector | Sell Plan | 8444,971 held (−0%) | $189.00 | $16K | +59.7% | — |
| Nov 5SEC | John W KozarichDirector | Sell Plan | 4944,922 held (−0%) | $190.26 | $9K | +58.6% | — |
| Oct 3SEC | John W KozarichDirector | Sell Plan | 19645,302 held (−0%) | $178.41 | $35K | +69.2% | — |
| Oct 3SEC | John W KozarichDirector | Sell Plan | 15545,147 held (−0%) | $180.01 | $28K | +67.7% | — |
| Oct 3SEC | John W KozarichDirector | Sell Plan | 9245,055 held (−0%) | $181.18 | $17K | +66.6% | — |
| Oct 3SEC | John W KozarichDirector | Sell Plan | 2445,498 held (−0%) | $177.60 | $4K | +69.9% | — |
Insiders at LIGAND PHARMACEUTICALS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Octavio EspinozaCFO | — | $13.0M | Aug 14, 2026 | — |
| Andrew ReardonGeneral Counsel | — | $10.3M | Oct 6, 2026 | — |
| Jason HaasDirector | — | $3.7M | Aug 14, 2026 | — |
| John L LamattinaDirector | — | $2.4M | Jun 12, 2026 | — |
| Nancy Ryan GrayDirector | — | $1.4M | Nov 12, 2025 | — |
| Jason AryehDirector | — | $1.2M | Jun 12, 2026 | — |
| John W KozarichDirector | — | $1.2M | May 14, 2026 | — |
| Stephen L SabbaDirector | — | $1.2M | Jun 18, 2026 | — |
| Martine ZimmermannDirector | — | $342K | Sep 14, 2026 | — |
LGND stock: common questions
Are LIGAND PHARMACEUTICALS INC insiders buying LGND stock?
In the past 12 months, 0 insiders reported open-market purchases of LGND worth $0.
Are LIGAND PHARMACEUTICALS INC insiders selling LGND stock?
9 insiders reported sales worth $34.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is LGND's 52-week range?
Over the past year LGND has traded between $177.73 and $322.61. It last closed at $301.81 on Oct 9, 2026.